Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.

Nicole Pedra is a disability advocate, influencer, actress and model who was diagnosed with multiple sclerosis at age 10, but chose to keep it private for two decades. In this episode of “Enable: The ...

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

Learn how early diagnosis and modern therapies can prevent Multiple Sclerosis from leading to long-term disability.

A retrospective chart review of pediatric patients with MS at a tertiary treatment center showed how the center’s first ...

Mediterranean, plant-based, and anti-inflammatory diets are associated with reduced C-reactive protein levels in people with multiple sclerosis.

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological conditions, according to a new study that analyzed cryopreserved CSF samples ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.